Cargando…
SARS-CoV-2 antibody seroprevalence and associated risk factors in an urban district in Cameroon
The extent of SARS-CoV-2 circulation in many African countries remains unclear, underlining the need for antibody sero-surveys to assess the cumulative attack rate. Here, we present the results of a cross-sectional sero-survey of a random sample of residents of a health district in Yaounde, Cameroon...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494753/ https://www.ncbi.nlm.nih.gov/pubmed/34615863 http://dx.doi.org/10.1038/s41467-021-25946-0 |
_version_ | 1784579383874289664 |
---|---|
author | Nwosu, Kene Fokam, Joseph Wanda, Franck Mama, Lucien Orel, Erol Ray, Nicolas Meke, Jeanine Tassegning, Armel Takou, Desire Mimbe, Eric Stoll, Beat Guillebert, Josselin Comte, Eric Keiser, Olivia Ciaffi, Laura |
author_facet | Nwosu, Kene Fokam, Joseph Wanda, Franck Mama, Lucien Orel, Erol Ray, Nicolas Meke, Jeanine Tassegning, Armel Takou, Desire Mimbe, Eric Stoll, Beat Guillebert, Josselin Comte, Eric Keiser, Olivia Ciaffi, Laura |
author_sort | Nwosu, Kene |
collection | PubMed |
description | The extent of SARS-CoV-2 circulation in many African countries remains unclear, underlining the need for antibody sero-surveys to assess the cumulative attack rate. Here, we present the results of a cross-sectional sero-survey of a random sample of residents of a health district in Yaounde, Cameroon, conducted from October 14 to November 26, 2020. Among the 971 participants, the test-adjusted seroprevalence of anti-SARS-CoV-2 IgG antibodies was 29·2% (95% CI 24·3–34·1). This is about 322 times greater than the 0.09% nationwide attack rate implied by COVID-19 case counts at the time. Men, obese individuals and those living in large households were significantly more likely to be seropositive, and the majority (64·2% [58·7–69·4]) of seropositive individuals reported no symptoms. Despite the high seroprevalence, most of the population had not been infected with SARS-CoV-2, highlighting the importance of continued measures to control viral spread and quick vaccine deployment to protect the vulnerable. |
format | Online Article Text |
id | pubmed-8494753 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-84947532021-10-07 SARS-CoV-2 antibody seroprevalence and associated risk factors in an urban district in Cameroon Nwosu, Kene Fokam, Joseph Wanda, Franck Mama, Lucien Orel, Erol Ray, Nicolas Meke, Jeanine Tassegning, Armel Takou, Desire Mimbe, Eric Stoll, Beat Guillebert, Josselin Comte, Eric Keiser, Olivia Ciaffi, Laura Nat Commun Article The extent of SARS-CoV-2 circulation in many African countries remains unclear, underlining the need for antibody sero-surveys to assess the cumulative attack rate. Here, we present the results of a cross-sectional sero-survey of a random sample of residents of a health district in Yaounde, Cameroon, conducted from October 14 to November 26, 2020. Among the 971 participants, the test-adjusted seroprevalence of anti-SARS-CoV-2 IgG antibodies was 29·2% (95% CI 24·3–34·1). This is about 322 times greater than the 0.09% nationwide attack rate implied by COVID-19 case counts at the time. Men, obese individuals and those living in large households were significantly more likely to be seropositive, and the majority (64·2% [58·7–69·4]) of seropositive individuals reported no symptoms. Despite the high seroprevalence, most of the population had not been infected with SARS-CoV-2, highlighting the importance of continued measures to control viral spread and quick vaccine deployment to protect the vulnerable. Nature Publishing Group UK 2021-10-06 /pmc/articles/PMC8494753/ /pubmed/34615863 http://dx.doi.org/10.1038/s41467-021-25946-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Nwosu, Kene Fokam, Joseph Wanda, Franck Mama, Lucien Orel, Erol Ray, Nicolas Meke, Jeanine Tassegning, Armel Takou, Desire Mimbe, Eric Stoll, Beat Guillebert, Josselin Comte, Eric Keiser, Olivia Ciaffi, Laura SARS-CoV-2 antibody seroprevalence and associated risk factors in an urban district in Cameroon |
title | SARS-CoV-2 antibody seroprevalence and associated risk factors in an urban district in Cameroon |
title_full | SARS-CoV-2 antibody seroprevalence and associated risk factors in an urban district in Cameroon |
title_fullStr | SARS-CoV-2 antibody seroprevalence and associated risk factors in an urban district in Cameroon |
title_full_unstemmed | SARS-CoV-2 antibody seroprevalence and associated risk factors in an urban district in Cameroon |
title_short | SARS-CoV-2 antibody seroprevalence and associated risk factors in an urban district in Cameroon |
title_sort | sars-cov-2 antibody seroprevalence and associated risk factors in an urban district in cameroon |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494753/ https://www.ncbi.nlm.nih.gov/pubmed/34615863 http://dx.doi.org/10.1038/s41467-021-25946-0 |
work_keys_str_mv | AT nwosukene sarscov2antibodyseroprevalenceandassociatedriskfactorsinanurbandistrictincameroon AT fokamjoseph sarscov2antibodyseroprevalenceandassociatedriskfactorsinanurbandistrictincameroon AT wandafranck sarscov2antibodyseroprevalenceandassociatedriskfactorsinanurbandistrictincameroon AT mamalucien sarscov2antibodyseroprevalenceandassociatedriskfactorsinanurbandistrictincameroon AT orelerol sarscov2antibodyseroprevalenceandassociatedriskfactorsinanurbandistrictincameroon AT raynicolas sarscov2antibodyseroprevalenceandassociatedriskfactorsinanurbandistrictincameroon AT mekejeanine sarscov2antibodyseroprevalenceandassociatedriskfactorsinanurbandistrictincameroon AT tassegningarmel sarscov2antibodyseroprevalenceandassociatedriskfactorsinanurbandistrictincameroon AT takoudesire sarscov2antibodyseroprevalenceandassociatedriskfactorsinanurbandistrictincameroon AT mimbeeric sarscov2antibodyseroprevalenceandassociatedriskfactorsinanurbandistrictincameroon AT stollbeat sarscov2antibodyseroprevalenceandassociatedriskfactorsinanurbandistrictincameroon AT guillebertjosselin sarscov2antibodyseroprevalenceandassociatedriskfactorsinanurbandistrictincameroon AT comteeric sarscov2antibodyseroprevalenceandassociatedriskfactorsinanurbandistrictincameroon AT keiserolivia sarscov2antibodyseroprevalenceandassociatedriskfactorsinanurbandistrictincameroon AT ciaffilaura sarscov2antibodyseroprevalenceandassociatedriskfactorsinanurbandistrictincameroon |